A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment

Trial Profile

A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Epilepsy
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 1 Jul 2018 to 1 Jan 2019.
    • 21 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
    • 11 Sep 2017 Results (n=7) published in the Marinus Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top